Trevena (NASDAQ:TRVN) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Trevena, Inc. (NASDAQ:TRVN) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $1.70 and traded as high as $1.86. Trevena shares last traded at $1.84, with a volume of 1,956 shares trading hands.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. StockNews.com started coverage on shares of Trevena in a research report on Tuesday. They set a “sell” rating for the company. HC Wainwright reiterated a “neutral” rating and set a $5.00 target price on shares of Trevena in a report on Thursday, November 14th.

Trevena Stock Up 1.1 %

The stock’s fifty day moving average price is $1.70 and its two-hundred day moving average price is $3.35. The company has a market capitalization of $1.59 million, a PE ratio of -0.04 and a beta of 1.05.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The company had revenue of $0.28 million for the quarter. On average, equities research analysts forecast that Trevena, Inc. will post -23.04 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.